
Conference Coverage
27 days ago
AAOpt 2025: Fitting irregular corneasabout 1 month ago
What ODs and MDs learned outside their specialties at EyeCon 2025Latest Content

Interventional glaucoma: Redefining the optometrist’s role in modern glaucoma management

South Korea's MFDS receives NDA for Tenpoint Therapeutics' Brimochol PF for presbyopia

Fitting the future: How technology is refining specialty lens care

Study examines association between air pollutants and dry eye via gene involvement

Sydnexis releases phase 3 STAR trial results on SYD-101 0.01% for slowing myopia progression

Shorts






Podcasts
Videos
Optometry Times Digital Edition



Continuing Medical Education
All News

The Vision Council argued that broad product definitions in the investigations could lead to include optical goods in new tariffs moving forward.

Raman Bhakhri, OD, FAAO; Julie Rodman, OD, MS, FAAO; and Andrew Rixon, OD, provide retinal updates during the meeting.

NK is more common than recognized; early diagnosis is paramount.

Catch up on the top stories in optometry during the week of October 27-October 31.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

A variety of eye drops for dry eye took the stage at this year's conference.

A discussion with company executives who specialize in helping optometrists and optical shops design and launch their own branded frame collections.

Optometrists and industry leaders alike share exciting new developments in myopia management.

Gromacki, OD, MS, FAAO, FSLS, stated that the first step to retention is asking if a patient would consider contact lens wear.

Ensuring proper hydration of the eye takes more moonlight and lullabies.

Jennifer Tsai, OD, details what she found surprising in the study results during AAOpt's Academy 2025 meeting.

Susan Gromacki, OD, MS, FAAO, FSLS, stated that gas-permeable (GP) lens fitting has fallen to the wayside in optometric education.


The FDA acknowledged the primary efficacy end point was met but determined the data did not confirm the effectiveness of low-dose atropine in children, according to the company.





































































.png)


